Brief synopsis

The concordance between tissue and circulating tumor DNA testing is well-established. However, clinicians may be confronted with discrepant results, especially when performing tissue and liquid testing in parallel, and interpretation may not be so straightforward.

In this Vessel Briefing, we will address some basic concepts and provide case studies to raise awareness about this factor that affects treatment decisions.

Join us on January 12th, 2023. 5PM CET/6PM EET

Please join the conversation and post your comments, thoughts and questions below leading up the the briefing.

See you inside. Members have full access to this document

Your North Star in the Transformation of Precision Oncology

Consider applying to access:

  • Comprehensive Educational Programs
  • Ongoing Professional Development
  • Exclusive Access to the Vessel Community
Apply Now Already have an account? Member Login